Last reviewed · How we verify
B007
B007 is a small molecule that targets the PI3K/AKT signaling pathway.
B007 is a small molecule that targets the PI3K/AKT signaling pathway. Used for Advanced solid tumors with PI3K/AKT pathway alterations.
At a glance
| Generic name | B007 |
|---|---|
| Sponsor | Shanghai Jiaolian Drug Research and Development Co., Ltd |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
B007 works by inhibiting the activity of PI3K, a key enzyme in the PI3K/AKT signaling pathway, which is involved in cell proliferation and survival. This inhibition leads to a decrease in AKT activity, resulting in anti-tumor effects.
Approved indications
- Advanced solid tumors with PI3K/AKT pathway alterations
Common side effects
- Hyperglycemia
- Diarrhea
- Nausea
Key clinical trials
- A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy. (PHASE2, PHASE3)
- A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy (PHASE1)
- A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis. (PHASE2, PHASE3)
- A Clinical Study of B007 in the Treatment of Pemphigus. (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- B007 CI brief — competitive landscape report
- B007 updates RSS · CI watch RSS
- Shanghai Jiaolian Drug Research and Development Co., Ltd portfolio CI